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Introduction
The standard of care for locally advanced non-small
cell lung cancer is deﬁnitive chemoradiotherapy followed
by adjuvant immunotherapy.1 The addition of surgery to
the treatment paradigm is thought to provide further beneﬁt in carefully selected patients, when surgery is limited
to lobectomy.2,3 Bronchopleural ﬁstula (BPF) is a known
but rare complication of lung cancer resection, with an
incidence of <3% reported in the literature. Neoadjuvant
radiation therapy is thought to be a risk factor.4 BPF most
commonly occurs within the ﬁrst several weeks after surgery but can occur anytime postoperatively and is generally managed with surgical correction.5 Herein, we
present a case of a 48-year-old woman treated with trimodality therapy who developed a BPF 2 years after initial
therapy and was managed conservatively.

Case Presentation
A 48-year-old woman active smoker with an 80 packyear smoking history presented with shortness of breath,
cough, low-grade fevers, night sweats, and weight loss. On
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physical examination, she was found to be febrile with digital
clubbing and no ﬁndings on auscultation. Computed tomographic (CT) scan of the chest revealed a 3.3-cm cavitary
lesion of the left upper lobe. Initial ﬁne-needle biopsy was
inconclusive; however, 3 months later endobronchial ultrasound-guided biopsy was performed and the patient
received a diagnosis of poorly differentiated adenocarcinoma. Positron emission tomography/CT revealed an avid
cavitary primary and nonbulky lymphadenopathy (Fig. 1).
Magnetic resonance imaging of the brain was negative (stage
IIA cT2N2M0). Her case was presented at multidisciplinary
tumor board and treatment with neoadjuvant chemoradiotherapy followed by lobectomy was recommended.

Treatment
She received 60 Gy delivered in 30 fractions to her primary and mediastinal nodal disease with intensity modulated radiation therapy prescribed to the 90% isodose line
with concurrent cisplatin and etoposide. The planning
treatment volume received a maximum dose of 66.7 Gy
and a mean dose of 63.8 Gy. The volume of uninvolved
lung receiving greater than or equal to 20 Gy (V20Gy)
was 22%. The ipsilateral left main stem and branches of
the bronchus were within the planning treatment volume
and received full dose (Fig. 2). She tolerated therapy well
with only grade one dermatitis, fatigue, and pneumonitis.
Two months after chemoradiotherapy, the patient underwent thoracotomy, left upper lobectomy, mediastinal
lymph node dissection, and intercostal muscle ﬂap buttress to the bronchial stump. Postsurgical pathology
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Figure 1 Presenting positron emission tomography/computed
tomography. Representative positron emission tomography/
computed tomography coronal slice of the left upper lobe cavitary adenocarcinoma with hyper-metabolic rind and nonbulky
lymphadenopathy.

revealed pathologic complete response to neoadjuvant
therapy, with no tumor detected in the left upper lobe or
dissected lymph nodes. She recovered from surgery without complications and was discharged after 3 days.
Throughout the next 2 years, CT surveillance scans were
performed and notable for apical postradiation ﬁbrosis.
The patient continued to smoke.

Bronchopleural Fistula
The patient presented to sports medicine due to acute on
chronic left shoulder pain. A left shoulder magnetic resonance imaging was ordered, revealing a left pneumothorax,
nondisplaced left-sided rib fractures, as well as tendinosis of
the rotator cuff. The patient denied a history of fall or other

Figure 2 Intensity modulated radiation therapy treatment
plan. Radiation plan of the left upper lobe and mediastinal adenocarcinoma with representative coronal plane. Prescription
dose was 60 Gy in 2 Gy fractions to the 90% isodose line.
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trauma. Due to concern for recurrent malignancy, a positron
emission tomography/CT was performed which demonstrated a hypermetabolic rind around the surgical cavity
with extension into the pleural space. An ultrasound-guided
biopsy was negative for malignancy, showing chronic
inﬂammatory changes and ﬁbrovascular tissue. Subsequent
CT-guided biopsy conﬁrmed these ﬁndings. Her case was
reviewed at multidisciplinary tumor board, and the ﬁndings
were determined to be due to postradiation therapy changes.
She continued CT surveillance for the next 6 months with
interval development of an asymptomatic, loculated hydropneumothorax in the left lung apex, and peripheral BPF 24
months after surgery (Fig. 3). One-way valve placement was
considered, however, given that she was asymptomatic, continued surveillance imaging was elected. Subsequent CT
imaging for the next year demonstrated stable to slightly
improved hydropneumothorax. She continues to be under
surveillance with no evidence of disease 4 years from treatment, nor intervention 24 months from BPF diagnosis. She
continues to smoke, although has made signiﬁcant progress
toward cessation.

Discussion
BPFs are deﬁned as a communication between the
lobar, segmental, or major bronchus and the pleural space
and are most commonly associated with surgical procedures.6 They can be either central or peripheral, with central BPFs being deﬁned as communications between the
pleura and larger branches of the tracheobronchial tree,
and peripheral BPFs as communications with the pulmonary tree distal to the segmental bronchi.7 It follows then
that central BPFs are more often a complication of

Figure 3 Bronchopleural ﬁstula. Representative coronal computed tomography slice of the peripheral bronchopleural ﬁstula
2 years after tri-modality therapy.
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pulmonary surgery and can be detected on bronchoscopy.
Peripheral BPFs can have etiologies in addition to surgery
such as abscess, bronchiectasis, pneumonia, tuberculosis,
neoplasms and radiation, and largely depend on imaging
for detection, with small peripheral BPFs being potentially
more difﬁcult to diagnose.8 The most common cause for
BPFs is surgical lung resection with lobectomies reporting
a lower incidence rate (0.5%-1.2%) compared with pneumonectomies (4.5%).9,10 Central BPFs can lead to lifethreatening pneumothorax and infection and can be a
source for signiﬁcant morbidity and mortality.5
Chemoradiotherapy is thought to increase the risk of
postsurgical BPF. Li et al identiﬁed neoadjuvant radiation
(odds ratio [OR] 3.914; P = .009) and chemoradiotherapy
(OR 2.166; P = .004) as signiﬁcant independent risk factors for developing BPF, and neoadjuvant chemotherapy
alone was not found to be signiﬁcantly associated with
BPF (OR 1.857; P = .104).4 The onset of BPF is deﬁned as
early if occurring within 1 to 7 days after surgery, intermediate from 8 to 30 days, and late after 30 days. The
incidence of late-onset BPF is rare and varies from
months to years after surgery.11,12 Although the pathophysiology is still unclear, decreased bronchial mucosal
blood supply, impaired healing, and inﬂammation after
chemoradiotherapy are thought to play a role.13 In addition, our patient’s continued active smoking status suggests a concurrent active inﬂammatory process that may
have attributed to her late-onset BPF, as chronic inﬂammation has been shown to increase the risk of BPF, reinforcing the importance of smoking cessation even after
diagnosis and treatment.14,15 Given the difﬁculty of radiographically diagnosing small peripheral BPFs, and the
need to contextualize ﬁndings relative to the surgical and
radiation therapy ﬁelds, multidisciplinary evaluation
including all members of the treatment team is critical
to not over or underdiagnose BPFs after lung cancer
surgery.
Currently, no clinical consensus or guidelines for the
treatment of BPF exist; however, management usually
begins with the treatment of life-threatening complications of BPF including antibiotics, chest tube placement,
and ventilation, followed by ﬁstula occluding procedures
or surgical correction.9,12,14-16 Conservative management
can be a viable strategy for a subset of postlobectomy
patients with minor peripheral BPFs, occasionally resulting in spontaneous ﬁstula closure, although it is ambiguous if this strategy is effective for peripheral BPF detected
on CT.8,16 Our case was of a rare late peripheral BPF
found incidentally on imaging in an asymptomatic
patient. To the best of our knowledge, current recommendations are limited to acute or symptomatic presentations,
with no published cases of late peripheral BPF after trimodality therapy managed with surveillance.12,16 Due to
the asymptomatic and uncomplicated nature of her presentation, contrasted with the potential of complications
from an additional procedure or surgical intervention,
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surveillance was elected. Our case emphasizes the need
for multidisciplinary evaluation of lung cancer patients
to cater treatments and interventions to their unique
circumstances.

Conclusion
We present the case of a locally advanced lung cancer
patient successfully treated with tri-modality therapy with
a rare, delayed complication of BPF managed conservatively. Patients undergoing neoadjuvant radiation therapy
for lung cancer, particularly those that continue to smoke,
are at increased risk of developing BPF even years after
treatment. Treatments for late BPF in patients with lung
cancer should be tailored to the acuity of symptoms and
unique patient factors, and are best determined in a multidisciplinary manner.

References
1. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med.
2018;379:2342–2350.
2. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2)
and IIIB non-small-cell lung cancer: Mature results of Southwest
Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–
1892.
3. Behera M, Steuer CE, Liu Y, et al. Trimodality therapy in the treatment of stage III N2-positive non-small cell lung cancer: A National
Cancer Database analysis. Oncologist. 2020;25:e964–e975.
4. Li S, Fan J, Liu J, et al. Neoadjuvant therapy and risk of bronchopleural ﬁstula after lung cancer surgery: A systematic meta-analysis
of 14 912 patients. Jpn J Clin Oncol. 2016;46:534–546.
5. Lois M, Noppen M. Bronchopleural ﬁstulas: An overview of the
problem with special focus on endoscopic management. Chest.
2005;128:3955–3965.
6. Alpert JB, Godoy MCB, deGroot PM, Truong MT, Ko JP. Imaging
the post-thoracotomy patient: anatomic changes and postoperative
complications. Radiol Clin. 2014;52:85–103.
7. Bat{han G, Ceylan KC. Bronchopleural ﬁstula: Causes, diagnoses
and management. Dis Pleura. August 6, 2019.. Available at: https://
www.intechopen.com/chapters/68227. Published online.
8. Tsubakimoto M, Murayama S, Iraha R, Kamiya H, Tsuchiya N,
Yamashiro T. Can Peripheral bronchopleural ﬁstula demonstrated
on computed tomography be treated conservatively? A retrospective
analysis. J Comput Assist Tomogr. 2016;40:86–90.
9. Shekar K, Foot C, Fraser J, Ziegenfuss M, Hopkins P, Windsor M.
Bronchopleural ﬁstula: An update for intensivists. J Crit Care.
2010;25:47–55.
10. Cerfolio RJ. The incidence, etiology, and prevention of postresectional bronchopleural ﬁstula. Semin Thorac Cardiovasc Surg.
2001;13:3–7.
11. Zhang C, Pan Y, Zhang R-M, Wu W-B, Liu D, Zhang M. Late-onset
bronchopleural ﬁstula after lobectomy and adjuvant chemotherapy
for lung cancer. Medicine (Baltimore). 2019:98.
12. Noh D, Park C-K. The management of delayed post-pneumonectomy broncho-pleural ﬁstula and esophago-pleural ﬁstula. Korean J
Thorac Cardiovasc Surg. 2016;49:138–140.

4

N. Haldar et al

13. Yamamoto R, Tada H, Kishi A, Tojo T. Effects of preoperative chemotherapy and radiation therapy on human bronchial blood ﬂow. J
Thorac Cardiovasc Surg. 2000;119:939–945.
14. Duarte-Ribeiro F, Dias C, Mota M. Bronchopleural and pleurocutaneous ﬁstula in HIV patient with pulmonary tuberculosis. IDCases.
2017;9:82–84.

Advances in Radiation Oncology: XXX 2021
15. Mao R, Ying P-Q, Xie D, et al. Conservative management of empyemacomplicated post-lobectomy bronchopleural ﬁstulas: experience of consecutive 13 cases in 9 years. J Thorac Dis. 2016;8:1577–1586.
16. Fuso L, Varone F, Nachira D, et al. Incidence and management of
post-lobectomy and pneumonectomy bronchopleural ﬁstula. Lung.
2016;194:299–305.

